Dr. Theo Hatzipetros joined the ALS Therapy Development Institute in 2011. He is an in vivo pharmacologist who specializes in the field of neurodegeneration. Prior to joining the Institute, Theo worked on drug discovery for the treatment of Parkinson's Disease at FoldRx Pharmaceuticals. At the ALS Therapy Development Institute, Theo's efforts are focused on the development of novel animal models of ALS and on evaluating therapeutic strategies for the treatment of the disease. Theo, originally from Cyprus, received his doctorate in pharmacology from the Boston University School of Medicine for his thesis work on the neurotoxic effects of the psychostimulant methamphetamine.
Current role